Inclusion Criteria:

- Superficial bladder cancer

- Completion of transurethral resection of bladder tumor (TUR-Bt)

- Completion of BCG induction therapy after TUR-Bt. In principle, BCG induction therapy
consists of the successive weekly intravesical administration of 81 mg of
BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of
TUR-Bt.

- Age 20 to 80 years

- ECOG performance status of 0 or 1

- Bladder capacity ≥ 150 mL

- Capable of oral UFT administration

- Expected life prognosis ≥ 3 years

- Hematopoietic WBC ≥ 3,000/mm^3

- Neutrophil ≥ 1,500/mm^3

- Platelet ≥ 100,000/mm^3

- Hepatic AST and ALT ≤ 2 times upper limit of normal (ULN)

- Total bilirubin ≤ 1.5 mg/dL

- Hemoglobin ≤ 9.0 g/dL

- Creatinine ≤ 1.5 mg/dL

Exclusion Criteria:

- Bladder cancer located in prostatic part of the urethra

- Anamnesis of bladder cancer classified as cT2, cT3 or cT4

- Anamnesis of metastatic bladder cancer

- Anamnesis of upper urinary tract carcinoma in situ

- Anamnestic treatment of intravesical BCG administration within previous 6 months

- Prior anticancer chemotherapy or radiotherapy

- Severe complication

- Presence of contraindications for the administration of BCG or UFT

- Pregnancy, lactation